Vaccine could train body to fight coronavirus, say scientists

Vaccine could train body to fight coronavirus, say scientists

Vaccine could train body to fight coronavirus, say scientists

The company also said that vaccination with the candidate vaccine, provisionally labeled mRNA-1273, prevented viral replication in the lungs of mice in preclinical testing.

General Motors and Ford Motor both surged, closing up 9.63 per cent and 8.37 per cent, respectively, as the two automakers started to reopen their North American factories in a push to restart work in an industry that accounts for about 6 per cent of United States economic activity and employs almost 1 million people in the US. At least 300,000 people have succumbed to the disease.

Experts predict a safe and effective vaccine could take 12 to 18 months to develop.

Vaccines are biological products. Neutralizing antibodies, or titers, are a small subset of antibodies that bind to a virus in a manner that blocks infection.

Moderna, which has partnered with the National Institute of Allergy and Infectious Diseases in the trials, is pushing forward with a larger phase 2 study. According to The New York Times, Moderna was granted half a billion dollars by the government to quicken development of the vaccine.

The announced sent the company's shares surging more than 39 per cent in premarket trading.

Gross proceeds from the offering will be about $1.34 billion, topping the company's stated goal of $1.25 billion.

The above video explains how Moderna's potential COVID-19 vaccine works.

Shares in Nasdaq-listed Moderna nevertheless skyrocketed as much as 34.7 percent to $87.00 on the news.

A candidate vaccine for Covid-19 developed by the drug maker Moderna appears to generate an immune response similar to the response seen in people who have been infected by the virus and recovered, the company said Monday.

"It must be noted that this is a Phase 1 study which has an object of showing the vaccine is able to induce an antibody response and that the dose range is appropriate", Evans said.

A new COVID-19 vaccine now proceeds to phase 2 human trial-spearheaded by US -based firm Moderna.

All eight of those participants (four receiving 25 µg and four receiving 100 µg) had neutralizing antibodies at or above levels seen in those who recovered from COVID-19. Only one suffered from redness around the injection site.

After the results, the company has dropped the idea of administering 250 mcg doses to participants.

The next phase of clinical trials will start with 600 people, expanding to as many as 1,000 in July.

Three doses of the vaccine were tested: low, medium and high. Final information on the 250 microgram dosing was not available.

Three groups of 15 patients aged 18 to 55 received three different doses of the vaccine in the Phase 1 test, the complete results of which are not yet known. But generally speaking, the company's past mRNA studies have shown T cell activity in both preclinical and clinical studies. The Cambridge, Massachusetts, biotech is now hoping its coronavirus vaccine can be its first, eyeing full regulatory approval in 2021.

Related news

[an error occurred while processing the directive]